ASCO 2013 - Slide Presentation: Relationship of baseline PSA and degree of PSA decline to radiographic progression-free survival in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: Results from COU-AA-302

CHICAGO, IL USA (UroToday.com) - Presented by Charles J. Ryan,1 Anil Londhe,2 Arturo Molina,3 Matthew R. Smith,4 Johann S. de Bono,5 Peter F.A. Mulders,6 Dana Rathkopf,7 Fred Saad,8 Christopher J. Logothetis,9 Karim Fizazi,10 Howard I. Scher,7 Eric J. Small,1 Shannon Matheny,3 Thian Kheoh,3 and Thomas W. Griffin3 at the American Society of Clinical Oncology (ASCO) Annual Meeting - May 31 - June 4, 2013 - McCormick Place - Chicago, IL USA

Click HERE to listen to a podcast by Charles J. Ryan, MD, one of the authors of this study

Click HERE to view the poster from this session

1Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA; 2Janssen Research & Development, Raritan, NJ; 3Janssen Research & Development, Los Angeles, CA; 4Massachusetts General Hospital Center, Boston, MA; 5Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK; 6Radboud University Medical Centre, Nijmegen, The Netherlands; 7Memorial Sloan-Kettering Cancer Center, New York, NY; 8University of Montréal, Montréal, Québec, Canada; 9MD Anderson Cancer Center, Houston, TX; 10Institut Gustave Roussy, University of Paris Sud, Villejuif, France

 

The ASCO Annual Meeting brings together more than 25,000 oncology professionals from a broad range of specialties, making it an excellent venue for exploring the theme of the Meeting — "Building Bridges to Conquer Cancer."


asco x

 

View Full ASCO 2013 Coverage